MYWOT

Child safety

N/A

Confidence

0%

Trustworthiness

N/A

Confidence

0%

MALICIOUS CONTENT INDICATORS

Availability or unavailability of the flaggable/dangerous content on this website has not been fully explored by us, so you should rely on the following indicators with caution.

Chinabiotoday.com most likely does not offer any malicious content.

  • Siteadvisor

    Safety status

    N/A

  • SAFEBROWSING

    Safety status

    Safe

  • Phishtank

    Safety status

    N/A

Secure connection support

HTTPS

Chinabiotoday.com provides SSL-encrypted connection.

ADULT CONTENT INDICATORS

Availability or unavailability of the flaggable/dangerous content on this website has not been fully explored by us, so you should rely on the following indicators with caution.

Chinabiotoday.com most likely does not offer any adult content.

Audience

  • Gender

    The accuracy of the provided data is based on the latest estimates available to us and can significantly differ from the real-life website stats, so should be taken with caution.

    Men

    59.5%

    Women

    N/A

Popular pages

  • ChinaBio® Today

    ChinaBio® Today is the most widely-read source for China life science news and analysis. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and priva...

  • Top Stories

    Top Stories ChinaBio ® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investor...

  • News & Analysis

    News & Analysis Jiangsu Hengrui Pharma was approved to launch an azole antifungal to treat severe vulvovaginal candidiasis, commonly known as yeast infections. A novel oral therapy, Oteseconazole Caps...

  • Week in Review

    Week in Review Week in Review Summaries of each week's events in China biotech are provided free to all readers.  A weekly email newsletter providing direct links to these articles is also available -...

  • Industry Insights

    Industry Insights Vancouver’s Zymeworks announced that its BLA for zanidatamab, a HER2-targeted bispecific antibody, was accepted for review by China’s CDE as a second-line treatment for HER2-positive...

  • Featured Companies

    Featured Companies Companies that are shaping the China biotech industry...  WuXi Biologics out-licensed global rights for up to four pre-clinical bi- & multi-specific TCE antibodies to GSK in a $1.5 ...